latest news releases from the newsroom
Sciax Technology, Inc.
Sciax Announces Important Developmental Sale to Canadian Law Enforcement Customer
BAY CITY, Mich. and TORONTO, March 23, 2004 (PRIMEZONE) -- UgoMedia Interactive Corp. (Pink Sheets:UGMI) (name change to Sciax Corporation pending) announced today that it has completed delivery of a Wolf Pack tactical remote viewing system to a Canadian Law Enforcement Customer. The Canadian security agency ordering the system is engaged in interdiction operations and will use the product for testing and evaluation purposes.
Integra LifeSciences Holdings Corp.
Integra LifeSciences' JARIT Surgical Instruments Launches Redmond/R&B Instruments at 2004 AORN Congress
PLAINSBORO, N.J., March 23, 2004 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that JARIT(R) Surgical Instruments launched the Redmond/R&B Surgical Instrument line at AORN's 51st Congress in San Diego, California. The Redmond/R&B catalog includes a complete line of premium, innovative spinal and neurosurgical instruments manufactured with the highest quality workmanship available today. Integra's acquisition of the R&B instrument business in January allowed JARIT to offer the orthopedic surgeon and neurosurgeon this comprehensive catalog of premium hand held instruments.
Hufvudstaden: Correction of Annual Report 2003
STOCKHOLM, Sweden, March 23, 2004 (PRIMEZONE) -- In the "Proposed distribution of unappropriated earnings" in Hufvudstaden's Annual Report for 2003, the balance brought forward incorrectly refers to the Group instead of the Parent Company. The amount to be carried forward for the Parent Company after the dividend of SEK 1.20 per share should be SEK 1,934,591,231, not SEK 2,216,481,812 as was stated.
Song Networks Holding
Song Networks and Labs2 extend partnership with new agreement
STOCKHOLM, Sweden, March 23, 2004 (PRIMEZONE) -- Song Networks Svenska AB, the Swedish subsidiary of Song Networks Holding AB (Stockholmsborsen: SONW) has concluded a framework agreement with Labs2 for the supply of data communications. The new agreement is the result of rapid growth in new customers for Labs2, which created the need for new infrastructure solutions. The agreement is worth SEK 7 million for 2004 and will run over 3 years.
Maxim Pharmaceuticals Completes Phase 1 Pharmacokinetic Trial of Orally Dosed Histamine
STOCKHOLM, Sweden and SAN DIEGO, March 23, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that it has completed a Phase 1A pharmacokinetic trial of a new orally dosed histamine dihydrochloride drug candidate. The normal-volunteer pharmacokinetic trial is intended to determine the safe dose range for orally administered histamine, designated "HD-O" for initial research purposes. This trial provides the basis for further clinical trials of this product candidate in the treatment of chronic liver diseases including Hepatitis C, alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH).